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Ivabradine
A Ray of Hope for
Inappropriate Sinus Tachycardia*
Melvin M. Scheinman, MD,
Vasanth Vedantham, MD, PHD
San Francisco, California
Inappropriate sinus tachycardia (IST) is a poorly understood
dysrhythmia characterized by palpitations and activity in-
tolerance with an elevated daytime heart rate, exaggerated
heart rate response to exercise, and otherwise normal cardiac
structure and function. First described in 1979, the disorder
is most commonly diagnosed in young women but is not
limited to that population (1,2). In addition to symptoms
related to elevated heart rate, there are often dysautonomic
symptoms such as orthostatic intolerance, recurrent syn-
cope, gastrointestinal distress, and anxiety. Various abnor-
malities have been proposed to explain the pathophysiology
of IST, including autonomic nervous system dysfunction
(1), sinoatrial node (SAN) abnormalities (3), and anti–beta-
adrenergic receptor antibodies (4), with some proposing a
significant psychological overlay.
See page 1323
IST can be frustratingly difficult to treat (5). The main-
stays of therapy include negative chronotropic agents such as
beta-blockers and calcium channel blockers, often ineffec-
tual at doses high enough to cause intolerable side effects.
Medical management frequently requires a prolonged pe-
riod of trial and error, dose adjustments, and lifestyle
changes for the patient. For refractory disease, sinus node
modification using a variety of catheter ablation techniques
can be attempted (6,7). Although the short-term results of
ablation are generally good, symptoms and elevated heart
rate commonly recur after successful sinus node modifica-
tion. In addition, ablative procedures carry the risk of sinus
node suppression with the need for permanent pacing.
Other drugs used with unpredictable efficacy include cloni-
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relevant to the contents of this paper to disclose.dine, pyrodystigamine, and serotonin-specific reuptake in-
hibitors, leaving most of these patients both with persistent
symptoms as well as potential side effects of administered
drugs.
Clearly, what is needed is a treatment that can provide
long-term inhibition of SAN automaticity without engen-
dering unwelcome side effects. Over the past several de-
cades, the cellular basis of sinoatrial electrophysiology has
gradually come into focus. Unlike other cardiac myocytes,
which are quiescent during diastole unless excited by a
neighboring cell, SAN myocytes possess cell autonomous
mechanisms that permit depolarization during diastole, and
hence automaticity. According to a contemporary but hotly
debated model (8), cellular rhythmicity in the SAN results
from mutual entrainment of a membrane clock, driven by
oscillating inward and outward ionic currents at the plasma
membrane, and a calcium clock, driven by spontaneous
calcium release events from the sarcoplasmic reticulum (9).
A key component of the membrane clock is an inward
depolarizing cation current that is activated in early diastole
by hyperpolarization, known as the “funny current” or If
(10,11). Owing to cyclic nucleotide responsiveness, the
current–voltage relationship and kinetics of If change with
utonomic tone, such that diastolic depolarization occurs
ore rapidly with increasing sympathetic tone and more
lowly with enhanced vagal tone. If is thus an important
regulator of the SAN response to autonomic inputs.
If is carried by the hyperpolarization-activated cyclic
ucleotide–gated ion channels (Hcn1-4), members of the
oltage-gated ion channel superfamily (12). Of the 4 Hcn
soforms, Hcn4 is the most highly expressed in cardiac
issue. During vertebrate cardiogenesis, Hcn4 is initially
idely expressed, but subsequently becomes restricted to the
pecialized myocytes of the cardiac conduction system
13,14). In the developed human heart, it is highly expressed
n the central SAN (the area of densest autonomic inner-
ation), with a negative gradient of expression extending to
he peripheral SAN, atrioventricular node, and ventricular
onduction system (15). Cardiac-specific deletion of Hcn4
n mouse models using different methodologies results in
radycardia that varies from a sick sinus syndrome–like
isorder to lethal sinus arrest (16,17). Definitive proof that
cn4 is an important regulator of heart rate in humans has
ome from rare instances of loss-of-function mutations that
ause familial sinus bradycardia in the absence of other
ardiac abnormalities (18).
Because of its restricted expression pattern and key role in
AN function, blockade of Hcn channels would be pre-
icted to cause pure heart rate reduction without other
ardiovascular effects. Moreover, because If regulates the
AN firing rate under resting conditions as well as in
esponse to autonomic inputs, Hcn channels are attractive
argets for the treatment of IST, a condition in which both
utonomic and intrinsic cardiac mechanisms may be in-
olved. Ivabradine, a specific blocker of Hcn channels,
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used clinically for patients with symptomatic stable coronary
disease to reduce myocardial oxygen demand (20). Subse-
quent trials have tested or sought to test ivabradine in acute
coronary syndromes (21), in chronic angina with left ven-
tricular dysfunction (22), and in heart failure (23). Although
a few case reports and nonrandomized studies have sug-
gested that ivabradine may have efficacy for patients with
IST (24–26), defining the role of ivabradine in the routine
treatment of this disease using rigorous methods has not
been undertaken until the elegant study, a double-blind,
randomized, placebo-controlled trial with a crossover de-
sign, of Cappato et al. (27) in this issue of the Journal.
Patients were included if they had typical symptoms of IST
with average daytime heart rate 95 beats/min and/or
exaggerated heart rate response to exercise or orthostatic
challenge. The patients were randomized to receive either
ivabradine (using a stepwise dosing algorithm) or placebo
for 6 weeks, with subsequent crossover after a brief washout
period, permitting within-subject comparisons. Symptoms
and heart rate parameters were determined for each patient
on and off therapy. The results were striking: 75% of
IST-related symptoms were eliminated, with nearly 50% of
patients experiencing prompt and complete resolution of all
symptoms on the drug. Ivabradine consistently lowered
daytime, nighttime, and maximum ambulatory heart rates.
In addition, exercise capacity improved with ivabradine in
association with a marked decrease in maximum heart rate
on a treadmill test, alleviating one of the hallmarks of the
disease. Adverse events were infrequent, with only 1 patient
stopping the drug because of visual changes, a known and
reversible side effect of the drug. Taken together, the results
suggest great promise for ivabradine with an excellent side
effect profile for many, if not most, patients with IST.
What about the patients who did not experience symp-
tom resolution with the medication? Because this relatively
small study was not powered to do subgroup analysis, we can
only speculate about why some subjects did not benefit as
much from the drug. For some, a longer course of therapy
might have provided some additional benefit, as was found
in a case series of IST patients taking ivabradine for up to 9
months (24). To the extent that systemic dysautonomia is
responsible for some symptoms, pure heart rate reduction
might not be expected to provide complete relief. Addition-
ally, functional abnormalities in other components of SAN
machinery such as the calcium clock might play important
roles in the pathophysiology of IST and might not be
responsive to ivabradine. In addition, possible benefits of
combining ivabradine with beta-blockers were not defined.
What, if anything, do the results of this trial teach us
about the pathophysiology of IST? Ivabradine is a pure
heart rate reducer, so the positive response to therapy clearly
implicates the elevated heart rate as a major contributor to
the symptoms experienced by IST patients. However, be-
cause If functions at the interface between the autonomicervous system and the heart, the data cannot settle theuestion of whether IST is a primarily cardiac or extracar-
iac disorder or a combination of the 2. However, if the
fficacy of ivabradine holds up in larger studies and the drug
ecomes first-line therapy for IST, settling this question
ay be of less clinical importance.
In summary, the rigorous methodology and positive
esults of this study provide compelling evidence of the
hort-term efficacy of ivabradine in IST. However, the
ong-term safety and efficacy are not defined. Therefore,
efore ivabradine can be routinely adopted as first-line
herapy, additional data on long-term efficacy and long-
erm safety will be needed in this patient population, as will
tudies involving multiple centers and larger numbers of
atients. Data from other large studies of ivabradine use in
icker patient populations (22,23) suggest that the drug is
ikely to be well tolerated by the majority of patients, even
ith long-term use, but a larger and long-term randomized
rial in IST patients will be required nonetheless. The study
y Cappato et al. (27) provides a superb rationale for
nitiating such a trial without delay. Until then, because IST
s a rare disease, consideration of drug approval under the
rphan or compassionate route should be seriously consid-
red for those with IST and disabling symptoms.
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